DPP4 and cancer: These subgroups were significantly different in terms of UACR, UNAPCR, UPCR, height, weight, BMI, SBP, DBP, HbA1c, glucose, eGFR, HDL cholesterol, TG, GPT, Hb, the proportions of female patients, patients with hypertension, cancer, and glomerular disease, and patients using dipeptidyl peptidase-4 (DPP-4) inhibitors, renin-angiotensin system (RAS) blockade, hypertensive drugs, and insulin.